Allstate Corp Has $5.31 Million Stake in Boston Scientific Corporation $BSX

Allstate Corp lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1,432.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,377 shares of the medical equipment provider’s stock after buying an additional 50,829 shares during the quarter. Allstate Corp’s holdings in Boston Scientific were worth $5,309,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific during the second quarter worth $37,000. CX Institutional lifted its holdings in shares of Boston Scientific by 1.9% in the second quarter. CX Institutional now owns 8,860 shares of the medical equipment provider’s stock valued at $952,000 after purchasing an additional 165 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Boston Scientific by 8.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 13,079 shares of the medical equipment provider’s stock worth $1,405,000 after acquiring an additional 1,017 shares in the last quarter. Finally, Bouvel Investment Partners LLC raised its holdings in shares of Boston Scientific by 1.8% in the second quarter. Bouvel Investment Partners LLC now owns 45,948 shares of the medical equipment provider’s stock valued at $4,935,000 after purchasing an additional 800 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on BSX shares. Oppenheimer cut their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday. Barclays raised their target price on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Cowen reissued a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Robert W. Baird boosted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, Truist Financial dropped their price objective on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $123.89.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Price Performance

BSX stock opened at $88.13 on Monday. The firm has a 50 day moving average of $96.90 and a 200-day moving average of $100.27. The firm has a market capitalization of $130.65 billion, a P/E ratio of 47.13, a price-to-earnings-growth ratio of 1.56 and a beta of 0.67. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the company posted $0.63 EPS. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 93,095 shares of company stock valued at $9,305,450 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.